Philip Mease
About
Philip Mease is a scholar working on Rheumatology, Immunology and Hematology.
According to data from OpenAlex, Philip Mease has authored 21 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Rheumatology, 14 papers in Immunology and 6 papers in Hematology. Recurrent topics in Philip Mease's work include Psoriasis: Treatment and Pathogenesis (12 papers), Spondyloarthritis Studies and Treatments (12 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). Philip Mease is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (12 papers), Spondyloarthritis Studies and Treatments (12 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). Philip Mease collaborates with scholars based in United States, United Kingdom and Germany. Philip Mease's co-authors include Peter Nash, Dafna D. Gladman, Daniel O. Clegg, Christian Antoni, Lesley M. Arnold, Stuart Silverman, Shephard Mpofu, Iain B. McInnes, Arthur Kavanaugh and Fujun Wang and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and Psychosomatic Medicine.
In The Last Decade
Philip Mease
21 papers receiving 1.3k citations
Hit Papers
Peers
Philip Mease
Joy Feld Israel
Avani Joshi United States
Alessandra Narcisi Italy
Laura Pina Vegas France
Adam Young United Kingdom
Yun‐Ting Chang Taiwan
Maria Bova Italy
Fabio Basta Italy
R. Ortega Castro Spain
Jeffrey M. Sobell United States
Citations per year, relative to Philip Mease Philip Mease (= 1×)
peers
Joy Feld
Countries citing papers authored by Philip Mease
Since
Specialization
Citations
This map shows the geographic impact of Philip Mease's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Mease with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Mease more than expected).
Fields of papers citing papers by Philip Mease
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Philip Mease. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Mease. The network helps show where Philip Mease may publish in the future.
Co-authorship network of co-authors of Philip Mease
This figure shows the co-authorship network connecting the top 25 collaborators of Philip Mease. A scholar is included among the top collaborators of Philip Mease based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Mease. Philip Mease is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Colombel, J F, Remo Panaccione, Hiroshi Nakase, et al.. (2022). P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications. Journal of Crohn s and Colitis. 16(Supplement_1). i514–i514.
2.
Mease, Philip, Philip Helliwell, Dafna D. Gladman, et al.. (2021). EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19 SUBUNIT OF IL-23, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-52 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES.
3.
McInnes, Iain B., Philip Mease, Dafna D. Gladman, et al.. (2020). Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study. Griffith Research Online (Griffith University, Queensland, Australia). 72. 1819–1822.
4.
Mease, Philip, Arthur Kavanaugh, Dafna D. Gladman, et al.. (2020). Characterization of Remission in Patients with Psoriatic Arthritis Treated with Upadacitinib: Post-hoc Analysis from Two Phase 3 Trials. Griffith Research Online (Griffith University, Queensland, Australia). 72. 2734–2736.
5.
Merola, Joseph F., Alice B. Gottlieb, Philip Mease, et al.. (2020). 13350 Psoriasis outcomes in a randomized trial of etanercept and methotrexate as monotherapy or in combination in patients with psoriatic arthritis. Journal of the American Academy of Dermatology. 83(6). AB118–AB118.
6.
Mease, Philip, Mark C. Genovese, Michael E. Weinblatt, et al.. (2018). Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response.. Arthritis & Rheumatism.
7.
Mease, Philip. (2018). Biologic treatments for psoriatic arthritis apart from TNF inhibition. Oxford University Press eBooks.
8.
Nash, Peter, Philip Mease, Iain B. McInnes, et al.. (2016). Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results From a Pooled Safety Analysis. Internal Medicine Journal. 46. 39–39.
9.
Tahir, Hasan, Philip Mease, Iain B. McInnes, et al.. (2015). 228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study. Lara D. Veeken.
10.
Mease, Philip, et al.. (2014). Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure. Data Archiving and Networked Services (DANS).
11.
Mease, Philip, Iain B. McInnes, Bruce Kirkham, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Data Archiving and Networked Services (DANS). 66.
12.
Gottlieb, Alice B., Philip Mease, Iain B. McInnes, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial. Queensland's institutional digital repository (The University of Queensland). 66.
13.
Mease, Philip, R Fleischmann, J. Wollenhaupt, et al.. (2013). EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE : 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY. Lara D. Veeken. 52(10). 162–163.
14.
Fürst, Daniel E., Joachim R. Kalden, Arthur Kavanaugh, et al.. (2013). Documentation of off-label use of biologics in Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 72. ii35–ii51.
15.
Mohs, Richard C., Philip Mease, Lesley M. Arnold, et al.. (2012). The Effect of Duloxetine Treatment on Cognition in Patients With Fibromyalgia. Psychosomatic Medicine. 74(6). 628–634.
16.
Arnold, Lesley M., Philip Mease, & Stuart Silverman. (2010). Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia.. PubMed. 16(5 Suppl). S138–43.
17.
Choy, Ernest, Philip Mease, Daniel K. Kajdasz, et al.. (2008). (186) Safety and tolerability of Duloxetine in the treatment of patients with Fibromyalgia: Analysis of 5 studies. Journal of Pain. 9(4). 22–22.
18.
Mease, Philip. (2006). Current Treatment for Psoriatic Arthritis and Other Spondyloarthritides. Rheumatic Disease Clinics of North America. 32. 11–20.
19.
Gladman, Dafna D., Christian Antoni, Philip Mease, Daniel O. Clegg, & Peter Nash. (2005). Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases. 64. ii14–ii17.
20.
Wanke, Lee A., Philip Mease, Alice B. Gottlieb, & Daniel Burge. (2004). Sustained improvement in activities of daily living and vitality in patients with psoriatic arthritis treated with etanercept. Journal of the American Academy of Dermatology. 50(3). P145–P145.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Joy Feld Breakdown of academic impact, for papers by Avani Joshi Breakdown of academic impact, for papers by Alessandra Narcisi Breakdown of academic impact, for papers by Laura Pina Vegas Breakdown of academic impact, for papers by Adam Young Breakdown of academic impact, for papers by Yun‐Ting Chang Breakdown of academic impact, for papers by Maria Bova Breakdown of academic impact, for papers by Fabio Basta Breakdown of academic impact, for papers by R. Ortega Castro Breakdown of academic impact, for papers by Jeffrey M. Sobell